

Journal of Biomaterials Applications

Synthesis and characterization of Fe₃O₄@GT/PVA nanocomposite for hydroxychloroquine sulfate (HCQ) delivery

Journal:	<i>Journal of Biomaterials Applications</i>
Manuscript ID	Draft
Manuscript Type:	Original Manuscript
Keywords:	PVA, GT, HCQ, drug release, nanocomposite, hydrogel
Abstract:	<p>Recent studies have shown the potential of hydroxychloroquine (HCQ) as a pharmaceutical agent to the treatment of a variety of cancers such as lung, melanoma, breast, pancreatic, and colon cancers. HCQ has been proposed to cure viral diseases such as Covid-19 disease. nowadays; Many studies for drug delivery of HCQ to the target site have been Developed through nanocomposite system. In this study, Fe₃O₄@PVA/GT nanocomposite has been synthesized for controlling HCQ release at pH 7.4. The influence of different factors were studied on the swelling and releasing rate such as the ratio of PVA to GT, the amount of Fe₃O₄ and the amount of crosslinking agent (citric acid), by the Tguchi method with 4 factors at 5 levels. The obtained results showed that increasing the amount of GT to PVA decreased the drug release rate. In improving the swelling, even a small amount of citric acid is effective, but its high amount reduces the swelling rate. After 18 hours, sample with PVA / GT ratio 100:0 (%wt), 2% CA (%wt) and 4% Fe₃O₄ (%wt) had the highest cumulative drug release (80.28 %) and sample with PVA / GT 85:15 (%wt), 4% CA (%wt) and 3% Fe₃O₄ (%wt) had the lowest cumulative drug release (39.28%).</p>

SCHOLARONE™
Manuscripts

Synthesis and characterization of $\text{Fe}_3\text{O}_4@GT/PVA$ nanocomposite for hydroxychloroquine sulfate (HCQ) delivery

Abstract:

Recent studies have shown the potential of hydroxychloroquine (HCQ) as a pharmaceutical agent to the treatment of a variety of cancers such as lung, melanoma, breast, pancreatic, and colon cancers. HCQ has been proposed to cure viral diseases such as Covid-19 disease. nowadays; Many studies for drug delivery of HCQ to the target site have been Developed through nanocomposite system. In this study, $\text{Fe}_3\text{O}_4@PVA/GT$ nanocomposite has been synthesized for controlling HCQ release at pH 7.4. The influence of different factors were studied on the swelling and releasing rate such as the ratio of PVA to GT, the amount of Fe_3O_4 and the amount of crosslinking agent (citric acid), by the Tguchi method with 4 factors at 5 levels. The obtained results showed that increasing the amount of GT to PVA decreased the drug release rate. In improving the swelling, even a small amount of citric acid is effective, but its high amount reduces the swelling rate. After 18 hours, sample with PVA / GT ratio 100:0 (%wt), 2% CA (%wt) and 4% Fe_3O_4 (%wt) had the highest cumulative drug release (80.28 %) and sample with PVA / GT 85:15 (%wt), 4% CA (%wt) and 3% Fe_3O_4 (%wt) had the lowest cumulative drug release (39.28%).

Keywords: PVA, GT, HCQ, hydrogel, drug release, CA, nanocomposite

1. Introduction:

1
2
3 Conventional drug delivery systems (DDSs), like pills and capsules, a slight dose of the drug
4 reaches the target site. The healthy tissues might also be affected due to passing through the
5 gastrointestinal tract or circulatory system [1, 2]; but Targeted drug delivery leads to the
6 accumulation of drugs in a specific body area. The main advantage of using targeted drug
7 delivery is to increase the therapeutic effects of the drug without inducing side effects on healthy
8 tissues and cells more [3,4]. The drugs can be delivered to the target tissues by magnetic field,
9 light, and heat. Among these, magnetic nanoparticles (MNPs) are widely used as targeting drug
10 carriers due to their high magnetic properties, fewer expences, and easy production [5,6].
11 However, MNPs are not used alone and are utilized in combination with other materials; because
12 the bare MNPs often have poor stability and dispersity [7,8].
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 Magnetic nanocomposites are a new area of research on superparamagnetic nanomaterials for the
28 targeted drug delivery using an external field. Supermagnetic Fe_3O_4 NPs can be an important
29 component of magnetic nanocomposites due to properties such as targeted transfer, local
30 hyperthermia treatment, and contrast enhancement for magnetic resonance imaging [9].
31 Hydrogels can be used as a second component of these nanocomposites, which can trap the drug
32 in their network structure and release the drug due to the high water absorption [10,11].
33
34
35
36
37
38
39
40

41 Nowadays, carboxymethylcellulose (CMC)-polyvinyl alcohol (PVA)- Fe_3O_4 magnetic
42 nanocomposites have been developed for long-term drug release. Citric acid, maleic anhydride
43 and glutaraldehyde can be used to make crosslink between network structure of these hydrogels.
44 The presence of -COOH groups in these hydrogels is useful because they are usually ionized at
45 physiological pH and are more desirable to deliver the drug to the target. The presence of OH
46 groups in PVA also increases the flexibility of the hydrogel film. In addition, crosslink agents
47 may hold drug molecules in the hydrogel matrix by hydrogen bonding and electrostatic
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 interactions between –OH and –COOH [12,13]. Among Natural polymers, Tragacanth gum (GT)
4 has been attracted much attention due to non-toxicity, biodegradability, biocompatibility, cost-
5 effectiveness and easy access, as well as wound healing, and suitable antimicrobial
6 properties[14]. This valuable natural substance obtained from Middle East farms can be a good
7 alternative to industrial hydrogels such as PVA. It is sensitive to pH and therefore can be used as
8 a smart drug carrier sensitive to physiological pH [15,16].
9

10
11
12 In this project, a novel PVA /GT/Fe₃O₄ nanocomposite has been developed and
13 Hydroxychloroquine sulfate (HCQ) is used as a model to evaluate the drug release rate from
14 PVA /GT/Fe₃O₄ nanocomposite. HCQ known as a drug to treat certain types of malaria [17].
15 Treating rheumatoid arthritis, lupus erythematosus, and Porphyria cutanea tarda are other uses.
16 Also, it has been used to treat lung and intestine cancer. HCQ can act as a promising chemical
17 sensitizer and immunomodulator for lung cancer chemotherapy. To treat some cancers, HCQ is
18 mainly taken orally, which causes much damage to the cells. For lung cancer, drug can be
19 directly delivered into the lungs by inhalation and in powder form to reach higher doses of the
20 drug to the lungs and reduce the negative effects of the drug on other areas [1,2]. HCQ, with the
21 outbreak of coronavirus (Covid-19), is used as an experimental drug for this disease. HCQ
22 affects the entry of the corona virus in cells and raises the pH of the endosome. In addition, the
23 process of endocytosis and the phenomenon of virus replication are eliminated. Therefore, HCQ
24 plays an important role in viral infections[19].
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47
48 According to researches; transmission of this drug to cancerous tissues by drug carriers can help
49 improve the disease process; Because the drug reaches the target site and the drug release rate
50 can be controlled[18].
51
52
53
54
55
56
57
58
59
60

1
2
3 Because HCQ is soluble in water, liposomes (such as PEG), polymeric NPs (such as PLGA), and
4
5 Niosomes (such as Pluronic F-127) can be used for delivery systems of this drug [20]. Nano-
6
7 carriers based on Fe_3O_4 have also been used as a suitable carrier of this drug (for example
8
9 $\text{Fe}_3\text{O}_4@\text{SiO}_2@\text{GLYMO}@$ pectin). Due to their good magnetic properties, they can deliver the
10
11 drug to the desired location with an external magnetic field [9].
12
13
14
15
16
17
18
19
20
21

22 In this project, hydrogel of poly vinyl alcohol (PVA) and tragacanth gum (TG) has been used for
23
24 the targeted drug delivery system. Citric acid as a crosslinking agent is more preferred to maleic
25
26 anhydride and glutaraldehyde due to its non-toxicity.
27
28

29 Finally, using taguchi method, parameters such as the ratio of PVA to GT, the amount of citric
30
31 acid, and the amount of iron oxide in the HCQ release rate are examined; then, the sample with
32
33 the most drug release will be selected as the optimal sample for PVA / GT / Fe_3O_4 magnetic
34
35 hydrogel in the short term. Taguchi is one of the methods for optimizing experiments. This
36
37 method uses orthogonal arrays (OA) to reduce the number of experiments [22]. In summary, the
38
39 purpose of the Taguchi method is to be able to observe and identify output changes by making
40
41 changes to process input variables and analyzing variance.
42
43
44
45
46
47
48
49

50 **2. Materials and methods**

51 **2.1 Materials:**

52
53
54
55
56
57
58
59
60

1
2
3 Hydroxychloroquine sulfate (Figure 1) was prepared from Amin Pharmaceutical Company (Iran),
4 tragacanth gum (GT, MW=50000-100000) (Iran) was obtained from Iranian farms, and polyvinyl
5 alcohol (PVA, MW: 10000-30000), $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$, citric acid (CA), NH_4OH and
6
7
8 Buffer pill containing KCl, NaCl, Na_2HPO_4 and K_2HPO_4 were prepared from Sigma Aldrich.
9
10
11
12
13
14
15

16 Fig. 1.

17 2.2 Synthesis of Fe_3O_4 :

18
19
20 The co-precipitation method was used to synthesize Fe_3O_4 nanoparticles [23]. First, 1 gram of
21 $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ and 1.62 gram of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ was dissolved in 40 ml of distilled water and stirred
22
23
24 1h. Then, ammonium hydroxide (NH_4OH , 0.5 M) was added dropwise to the solution and stirred
25
26 for 1h (pH=11). As much as 2% w/w citric acid as a coating agent was added to the obtained
27
28 solution for modification of Fe_3O_4 nanoparticles. The obtained Fe_3O_4 nanoparticles was
29
30 separated by magnet and washed several times by the distilled water. Finally, the sediment was
31
32 placed in an oven at 40 °C for 24 hours to be dried completely. SEM, FTIR, and VSM were used
33
34 to characterize the structure and properties of the obtained nanocomposite.
35
36
37
38
39

40 2.3 Synthesis of Fe_3O_4 @PVA/GT hydrogel:

41
42
43 Different proportions of PVA (0.8-1g) and GT (0-0.2g) were stirred in 20 ml distilled water
44 using a mechanical stirrer; the solution was heated to 80 °C to form a gel. After 5 minutes, CA
45 (0.01-0.05g) was added to it. Finally, the Fe_3O_4 nanoparticles (0.01-0.05g) were added and then
46
47 stirred until the nanoparticles were completely dispersed.
48
49
50

51 At the end, the solution was poured into the petri dish and put in the oven at 40 °C to dry [12].
52 The produced film was placed in the oven and heated to 130 °C for a specified time (1-5 min) to
53
54
55
56
57
58
59
60

1
2
3 initiate crosslinking reaction. Figure 2 shows a schematic representation for synthesis of
4 $\text{Fe}_3\text{O}_4@$ PVA/GT hydrogel.
5
6
7
8
9

10 Fig. 2
11
12
13
14
15

16 **2.4 Experimental design**

17
18 The number of samples for the experiment was determined using Taguchi method with 4 factors
19 and 5 levels (Table 1). The effect of parameters on the drug releasing including PVA:GT ratio,
20 CA crosslinker wt.%, Fe_3O_4 wt.%, and crosslinking time (min) were investigated.
21
22
23
24
25

26 **Table 1**

27
28 Here, L25 (5^6) ANOVA was selected, which shows 25 experiments with 5 levels, 4 factors
29 orthogonal array (Table 2).
30
31
32
33

34 **Table 2.**

35 **2.4 Swelling study:**

36
37 The quality of swelling can examine transverse bonds and chemical interactions between
38 nanoparticles and hydrogels. 0.2 g of hydrogel film was placed in a dialysis bag and put in 20 ml
39 of PBS buffer and the swollen film sample was removed from the buffer at different intervals (
40 0.5, 1, 3, 6, 12, and 18h). Their surface water was dried with a paper towel and weighed. The
41 swelling ratio was determined using the following equation.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

$$\text{Swelling ratio} = \frac{(W_t - W_d)}{W_d} \quad (1)$$

Where, W_d is the weight of the dried gel before swelling and W_t is the weight of the swollen gel at time t .

2.5 Drug loading and release study

1 g of the film was dissolved in 10 ml distilled water to form a hydrogel. 0.02 gr of HCQ (table 1) was added to it. The hydrogel was stirred for 12 hour to load the HCQ in the hydrogel network and was dried in petri dishes at 40°C for 18 hour.

The in-vitro release experiments were studied in buffered solution at pH=7.4 and temperature 37 °C. 1 gram of the prepared film was placed in beaker contain 10 ml PBS with pH=7.4 to slowly turn into a hydrogel. At certain time intervals, 2 ml PBS was removed from beaker to determine drug release by spectrophotometry. Drug release was calculated via spectrophotometry at $\lambda_{\text{max}}=343$ nm. After removing 2 ml of the sample for testing, the same amount of PBS was added to beaker to keep the volume constant.

2.6 Characterization:

X-Ray Diffraction (XRD) model Philips PW3040 was used to confirm the crystalline structure of Fe_3O_4 nanoparticles. Fourier Transmission Infrared Spectroscopy (FT-IR) model Lumex infralum FT-08 was utilized to investigate the coating of Fe_3O_4 particles and analysis of the nanocomposite. Vibrating Sample Magnetometer (VSM) model 7404 made in Lake Shore Cryotronics Company was used for the measurement of magnetic properties. FE-SEM was performed with a ZEISS Sigma 300 scanning electron microscope operating at 15Kv to observe

1
2
3 surface morphology of nanocomposite. For investigating the release of HCQ from
4 nanocomposite, Shimadzu brand UV-Vis model 1900i was selected. Minitab software was used
5
6
7
8 for Taguchi design to optimize the number of experiments.
9

10 **3. Results and discussion:**

11 **3.1 Coating of Fe₃O₄:**

12
13
14
15
16
17 Many studies have been done to investigate the toxicity of MNPs. The results showed that they
18 had significant toxicity on some tissues and cells. Prepared MNPs is coated citric acid
19 to decrease toxicity and enhance stability. it is used as a coating agent due to it biocompatibility
20 because the MNPs surface may be exposed to biological agent. The coating of MNPs inhibits
21 agglomeration and oxidation and improves their dispersion in a suspension[7].
22
23
24
25
26
27

28
29 X-ray diffractograms (XRD) of the CA-coated MNPs are shown in figure 3. A series of peaks
30 were observed at $2\theta = 18.28, 30.19, 31.78, 35.71, 43.45, 53.55,$ and 63.32 , which are in good
31 accordance with the cubic phase of Fe₃O₄ (Reference code: JPCD-00-001-1111 and JPCD-00-
32 002-1035). The peaks are sharp and intense confirming the formation of highly crystalline
33 MNPs. The crystallite size of MNPs was calculated using Debye Scherer equation [7,8].
34
35
36
37
38
39
40
41

42 **Fig. 3.**

43
44
45 FT-IR of CA-coated and uncoated MNPs are compared in Figure 4. FTIR shows the presence of
46 a functional group of coating agents on the particle surface of Fe₃O₄. For bare Fe₃O₄, the broad
47 band spectrum at 3420.16 cm^{-1} is due to the stretching vibration of O-H groups on the surface of
48 the Fe₃O₄ nanoparticles; some molecular water may be trapped in the crystalline structure of
49 Fe₃O₄. As a result, the broad band of the peak may be due to the OH bands of water. Coating
50
51
52
53
54
55
56
57
58
59
60

1
2
3 MNPs raised the broad band because of existence OH bands in citric acid. The C=O vibration of
4
5 COOH group in CA at 1710.35 cm^{-1} shifts to lower wavenumber with higher intensity at 1619.13
6
7 cm^{-1} revealing the binding of a CA radical to surface of Fe_3O_4 MNPs by adsorption of
8
9 carboxylate (citrate) ions. It can be attributed to the formation of an iron complex with C=O,
10
11 which weakens the C=O bond.
12
13

14
15 The 1385.17 cm^{-1} and 1078 cm^{-1} peaks are due to the symmetric stretching of COO^- and C=O
16
17 and OH groups. The strong absorption band in 568.52 cm^{-1} is related to the Fe-O stretching band
18
19 [7,8].
20
21
22
23
24
25

26 **Fig. 4.**
27
28
29
30
31

32
33 Field dependent magnetization (M vs. H) plot at 300K (Fig 5.) show superparamagnetic behavior
34
35 of coated MNPs without magnetic hysteresis. The maximum magnetization was 65 emu/g. These
36
37 stable Fe_3O_4 nanoparticles with high magnetic response can be used for magnetic drug targeting.
38
39 The amount of nanoparticles in the hydrogel plays a major role in the quality of its transmission
40
41 by the magnetic field; its high amount makes the hydrogel more sensitive to the magnetic field.
42
43 Measurement of zeta potential showed that the surface charge of nanoparticles at neutral pH was
44
45 negative (24.6 mV).
46
47
48
49

50 **Fig. 5.**
51
52

53 SEM images of Fe_3O_4 MNPs are shown in figure 6, the surface of Fe_3O_4 nanoparticles are
54
55 roughness and have high agglomeratin with asymmetrical shape. might be due to the magnetic
56
57
58
59
60

1
2
3 dipole moment interaction. The particle size is in the nanometer range. agglomeratin of
4
5 nanoparticles is very undesirable because it disrupts their uniform dispersion in the hydrogel.
6
7
8
9
10

11
12 **Fig. 6.**
13

14 15 **3.2 Swelling behavior Fe_3O_4 @PVA/GT hydrogel:** 16

17
18 Figure 7 showed the swelling results in pH=7.4
19
20
21
22
23

24
25 **Fig. 7.**
26

27 Design of experiments (DOE) is used for analyzing the swelling results. Figures 8 and 9 show
28 the swelling average value of mean for 1 and 18 hours, at pH=7.4, respectively.
29
30

31
32
33 **Fig. 8.**
34
35
36
37
38
39
40
41

42
43
44
45
46
47
48
49 **Fig. 9.**
50
51

52 The increasing Fe_3O_4 nanoparticles strongly affects the swelling at pH= 7.4 (Fig.) due to the
53 elasticity reduction of the nanocomposite. The film of hydrogel becomes more fragile by
54 increasing Fe_3O_4 . Fe_3O_4 content can adjust the swelling behavior and magnetization of the
55 hydrogel; As a result, its amount is very important.
56

57 Increasing the amount of GT and Fe_3O_4 darkens the color of the hydrogel. Pure PVA swells
58 quickly, but swelling slows down by additional GT. Perhaps the reason is in GT networks as it
59
60

1
2
3 takes longer to open GT cells and absorb water. The elasticity of GT is lower than PVA, so
4
5 increasing it reduces the elasticity of the nanocomposite.
6
7

8
9 Cross-linking is required even in smaller amounts. Its absence causes the GT to separate from the
10
11 PVA network. The small amount of CA increases water absorption [7]. Its high amount reduces
12
13 water absorption and increases the fragility of hydrogels due to crosslinking. Extending the
14
15 crosslinking time gives CA a greater chance to crosslink. Figure 10 shows that by increasing the
16
17 reaction time, there will be a greater amount of the thermodynamically material of (a).
18
19
20
21
22
23
24
25
26
27

28 **Fig. 10.**

29
30 GT polysaccharide has many functional groups such as -COOH. Swelling increased due to the
31
32 presence of an increased number of hydroxyl and ester functional groups introduced by cross
33
34 linking the PVA/TG backbone with CA. The multiplicity of these groups not only increases the
35
36 swelling due to the interaction of water with OH and COOH groups but also changes the
37
38 interaction of the hydrogel with the HCQ [3,4].
39
40
41
42

43 **3.3 Release behavior of Fe₃O₄@PVA/GT:**

44
45
46 Figure 11 shows the results of drug release in pH 7.4. Values are expressed as a percentage of the
47
48 original value. The S/N ratio equation is shown below. S/N is selected based on larger-the-better.
49
50

$$51 \frac{S}{N} = -10 \lg \left(\frac{1}{n \sum_{i=1}^n y_i^2} \right) \quad (2)$$

1
2
3 In this equation, n is the number of repetitions per test ($n = 1$), and y is the percentage of
4 cumulative drug release.
5
6
7
8
9
10

11 **Fig. 11.**
12
13
14
15
16
17

18 **Fig. 12.**
19
20
21
22
23

24 **Fig. 13.**
25
26
27

28 It is clear that increasing the Fe_3O_4 has intensified the HCQ release due to the disruption of the
29 network structure by solid particles (Fig. 13). A large amount of nanoparticles causes
30 agglomeration in parts of the hydrogel and its weight balance can be disturbed (Fig. 15). Also,
31 increasing the amount of GT reduces the drug release. As a result, these parameters can change
32 the dosage of the HCQ. Increasing the amount of GT reduces the drug release. The presence of
33 COOH functional groups in the GT networks is a factor for reducing the rate of drug release
34 because of its more interaction with the drug.
35
36
37
38
39
40
41
42
43

44 The dosage of the HCQ depends on the patient's condition and the type of treatment [25-27].
45 Therefore, the type of hydrogel can be determined to release a certain amount of drugs. For
46 example, sample 4 is used when a high dose is required and sample 17 is employed when the
47 lowest dose is needed.
48
49
50
51
52
53

54 **3.4 FTIR results of $\text{Fe}_3\text{O}_4@GT/PVA$**

55
56
57
58
59
60

1
2
3 Figure 14 shows the FTIR of $\text{Fe}_3\text{O}_4@\text{PVA}/\text{GT}$ nanocomposite. The broad band spectrum at
4 3300-3700 cm^{-1} related to OH stretching from the intermolecular and intramolecular hydrogen
5 bonds of PVA and GT. The peak of the OH band widens with increasing GT, it is due to the
6 formation of a hydrogen band between the GT and PVA chains. The absorption bands in 2967
7 cm^{-1} is for asymmetric stretching vibrations of methylene groups in PVA. The band at 1748 cm^{-1}
8 can be attributed to carbonyl and C-O groups. The absorption bands are absorbed at about 1470
9 cm^{-1} and 1280 cm^{-1} as related to CH_3 and CH_2 bending. absorption bands can be seen at 1140
10 cm^{-1} (C-O stretching) and 970 cm^{-1} and 830 cm^{-1} (C=C bending) of TG [28-30].
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Fig. 14.

3.5 SEM results of $\text{Fe}_3\text{O}_4@\text{GT}/\text{PVA}$

32 Figure 15 shows the morphology of the $\text{Fe}_3\text{O}_4@\text{PVA}/\text{GT}$ nanocomposite. In SEM images, the
33 porosity on the surface of the hydrogel are well visible. In figure 15 (b) lumps can be caused by
34 the presence of Fe_3O_4 in the hydrogel. These nanoparticles are well coated by hydrogels.
35 However, nanoparticles are not well dispersed in the nanocomposite and have agglomerated in a
36 certain area, which is very undesirable. In figure 15 (d) a crack-like structure is observed for
37 nanocomposites, which is probably due to the prohibited movement of GT clusters in the cavities
38 of the PVA network [28-30].
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fig. 15.

3.6 Kinetic modeling

The drug release kinetics of HCQ for the sample with the highest release (sample 4) and the minimum release (sample 17) were investigated by fitting the zero-order via Higuchi and Hixon-Crowell models to determine the best kinetic model. The kinetic equations are specified below.

The maximum amount of R-squared (R^2) determines the best kinetic equation.

$$C = k_0t \quad (3) \text{ zero order}$$

$$Q = k_H t^{\frac{1}{2}} \quad (4) \text{ Higuchi}$$

$$Q_0^{\frac{1}{3}} - Q_t^{\frac{1}{3}} = k_{HC}t \quad (5) \text{ Hixon-Crowell}$$

In these equations, k is the constant value, t is release time, C is the concentration of drug release at time t , and Q is the amount of drug release at time t [15].

Table 3.

Clearly, the zero order kinetic equation is appropriate for the data. It can be observed from this equation that the drug release concentration has been continuous and slow over time.

The results of this study are compared with those of other studies as summarized in the following table.

Table 4.

4. Conclusion

1
2
3 In this project, Fe₃O₄@GT/PVA nanocomposite, magnetic and pH sensitive has been produced
4 to carry the hydroxychloroquine drug. Hydroxychloroquine is one of the most effective drugs
5 against some of cancers. For this nanocomposite, the ratio of PVA to GT, the amount of citric
6 acid crosslinker, and Fe₃O₄ on the quality of swelling and drug release was investigated. The
7 swelling of this nanocomposite was examined at neutral pH. The results showed that increasing
8 the amount of Fe₃O₄ caused the fragility of dry nanocomposite and reduced swelling and
9 increased drug release. The presence of citric acid is beneficial, but high amount of it reduce
10 swelling. Adding GT to PVA reduces the rate of drug release.
11
12
13
14
15
16
17
18
19
20
21

22 **Declaration of competing Interest**

23
24
25 The authors declare that there are no competing financial interests.
26
27

28 **Acknowledgments:**

29
30
31 The authors would like to express their gratitude to Islamic Azad University, Najafabad, Iran.
32
33

34 **References**

- 35
36
37
38
39
40 1. Li Y, Cao F, Li M, et al. Hydroxychloroquine induced lung cancer suppression by
41 enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like
42 macrophages. *J Exp Clin Cancer Res* 2018; 37: 259.
43
44 2. Manic G, Obrist F, Kroemer G, et al. Chloroquine and hydroxychloroquine for cancer
45 therapy. *Mol Cell Oncol* 2014;1(1):29911.
46
47 3. Poorvashree J, Suneela D. Novel drug delivery of dual acting prodrugs of
48 hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological
49 study. *Drug Deliv Transl Res* 2017;7(5):709-730.
50
51 4. Gadhave RV, Mahanwar PA, Gadekar PT. Effect of glutaraldehyde on thermal and
52 mechanical properties of starch and polyvinyl alcohol blends. *Des Monomers*
53 *Polym* 2019;22(1):164–170.
54
55
56
57
58
59
60

- 1
2
3 5. Goodarz Naseri M, Bin Saion E, Abbastabar Ahangar H, et al. Synthesis and
4 characterization of manganese ferrite nanoparticles by thermal treatment method. *J Magn*
5 *Magn Mater* 2011;323:1745-1749.
6
- 7
8 6. Wangm G, Ma Y, Zhang L, et al. Facile synthesis of manganese ferrite/graphene
9 oxide nanocomposites for controlled targeted drug delivery. *J Magn Magn Mater* 2016
10 ;401:647–650.
11
- 12 7. Dheyab MA, Aziz AA, Jameel MS, et al. Simple rapid stabilization method through citric
13 acid modification for magnetite nanoparticles. *Sci Rep* 2020;10:10793.
14
- 15 8. Wei Y, Han B, Hu X, et al. Synthesis of Fe₃O₄ Nanoparticles and their Magnetic
16 Properties. *Procedia Eng* 2012;27:632-637.
17
- 18 9. Sadr MS, Heydarinasab A, Panahi HA, Javan RS. Production and characterization of
19 biocompatible nano-carrier based on Fe₃O₄ for magnetically hydroxychloroquine drug
20 delivery. *Polym Adv Technol* 2021;32:564–573.
21
22
- 23 10. Ponco A, Helmiyati H. Hydrogel of carboxymethyl cellulose and polyvinyl alcohol
24 modified by CuNPs as antibacterial in wound dressing. *AIP Conference Proceedings*
25 2020;2242:040009.
26
- 27 11. Luo YL, Zhang XY, Fu JY, et al. Novel temperature and pH dual-sensitive
28 PNIPAM/CMCS/MWCNT semi-IPN nanohybrid hydrogels: Synthesis, characterization,
29 and DOX drug release. *Int J Polym Mater* 2017;66:398– 409.
30
31
- 32 12. Ghorpade VS, Dias RJ, Mali KK, Mulla SI, Citric acid crosslinked
33 carboxymethylcellulose-polyvinyl alcohol hydrogel films for extended release of water
34 soluble basic drugs. *J Drug Deliv Sci Technol* 2019;52:421-430.
35
- 36 13. Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges. *Polymer*
37 2008;49:1993-2007.
38
- 39 14. Hosseini MS, Hemmati K, Ghaemy M. Synthesis of nanohydrogels based on tragacanth
40 gum biopolymer and investigation of swelling and drug delivery. *Int J Biol Macromol*
41 2015;82:806-815.
42
43
- 44 15. Shafiee S, Abbastabar Ahangar H, Saffar A. Taguchi method optimization for synthesis
45 of Fe₃O₄@ chitosan/Tragacanth Gum nanocomposite as a drug delivery system.
46 *Carbohydrate Polymers* 2019;222:114982.
47
48
- 49 16. Niknia N, Kadkhodae R, Eshtiaghi MN. Microbial Exopolysaccharides as Drug
50 Carriers. *Polymers (Basel)* 2020;157:151-157.
51
- 52 17. Lei ZN, Wu ZX, Dong S, et al. Chloroquine and hydroxychloroquine in the treatment of
53 malaria and repurposing in treating COVID-19. *Pharmacol Ther* 2020 Dec;216:107672.
54
55
56
57
58
59
60

18. Verbaanderd C, Maes H, Schaaf MB, et al. Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. *Ecancermedicalsecience* 2017;11:781.
19. Kavanagh O, Marie Healy A, Dayton F, et al. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19. *Med Hypotheses* 2020 ;143, 110110.
20. Stevens DM, Crist RM, Stern ST. Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine. *Molecules* 2020;26(1):175.
21. Schroeder RL, Gerber JP. Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies. *Toxicology Reports* 2014;1:963-968.
22. Pouretedal HR, Damiri S, Zandi A. Study the operating conditions on agglomeration of RDX particles in anti-solvent crystallization by using statistical optimization. *Defence Technology* 2019;15:233-240.
23. Ajinkya N, Yu X, Kaithal Pet al. Magnetic Iron Oxide Nanoparticle (IONP) Synthesis to Applications: Present and Future. *Materials* 2020;13:4644.
24. Truong YB, Choi J, Mardel J, et al. Functional Cross-Linked Electrospun Polyvinyl Alcohol Membranes and Their Potential Applications. *Macromol Mater Eng* 2017; 302:1700024.
25. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. *Clin Pharmacol Ther* 2020;108(4) :766-769.
26. Badgujar K, Badgujar AB, Patil VP, Dhangar DV. Hydroxychloroquine for COVID-19: A review and a debate based on available clinical trials/case studies. *J drug deliv ther* 2020;10(3):304-11.
27. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw pen* 2020;3(4):208857.

- 1
2
3
4 28. Kamoun EA, Kenawy ES, Chen X. A review on polymeric hydrogel membranes for
5 wound dressing applications: PVA-based hydrogel dressings. *J Adv Res* 2017;8(3):217-
6 233.
7
8
9
10 29. Ranjbar Mohammadi Bonab M, Prabhakaran M, Bahrami H, Ramakrishna S. Gum
11 tragacanth/poly (l-lactic acid) nanofibrous scaffolds for application in regeneration of
12 peripheral nerve damage. *Carbohydr Polym* 2015;140: 104-112.
13
14
15
16
17 30. Thambi T, Phan VH, Lee DS. Stimuli-Sensitive Injectable Hydrogels Based on
18 Polysaccharides and Their Biomedical Applications. *Macromol. Rapid Commun*
19 2016;37:1881–1896.
20
21
22
23 31. Zambuzi GC, Camargos CHM, Ferreira MP et al. Modulating the controlled release of
24 hydroxychloroquine mobilized on pectin films through film-forming pH and
25 incorporation of nanocellulose, *Carbohydr Polym* 2021; 2:100140.
26
27
28 32. Olejnik A, Goscianska J, On the importance of physicochemical parameters of copper
29 and aminosilane functionalized mesoporous silica for hydroxychloroquine release.
30 *Mater Sci Eng C* 2021;130: 112438.
31
32 33. Reddy SG. Controlled release studies of hydroxychloroquine sulphate (Hcq) drug-using
33 biodegradable polymeric sodium alginate and lignosulphonic acid blends. *Rasayan*
34 *Journal of Chemistry* 2021;14(4):2209-2215
35
36 34. Magne TM, Helal-Neto E, Correa LB et al. Rheumatoid arthritis treatment using
37 hydroxychloroquine and methotrexate co-loaded nanomicelles: In vivo results. *Colloids*
38 *Surf B* 2021; 206: 111952.
39
40 35. Armutcu C, Pişkin S. Evaluation of controlled hydroxychloroquine releasing
41 performance from calcium-alginate beads. *Hittite J Sci Eng* 2021; 8(3): 255-263.
42
43
44
45

46 **Figure captions**

47 **Fig. 1.** Structure of HCQ [21]

48 **Fig. 2.** Synthesis of Fe₃O₄@GT/PVA nanocomposite

49 **Fig. 3.** XRD pattern of the CA-coated Fe₃O₄

50 **Fig. 4.** FTIR spectrum of CA-coated Fe₃O₄

51 **Fig. 5.** VSM results of CA-coated Fe₃O₄

1
2
3 **Fig. 6.** SEM images of nanoparticles
4

5 **Fig. 7.** Diagram of swelling at different hours in pH 7.4
6

7
8 **Fig. 8.** Mean at levels 1-5 for each parameter at pH=7.4 and 1 hour swelling
9

10 **Fig. 9.** Mean at levels 1-5 for each parameter at pH=7.4 and 18-hour swelling
11

12
13 **Fig. 10.** Reaction of CA and PVA at 130 °C [24]
14

15 **Fig. 11.** Diagram of HCQ release in pH=7.4
16

17 **Fig. 12.** Mean at levels 1-5 for each factor at pH 7.4
18

19 **Fig. 13.** SN ratio at levels 1-5 for each factor at pH 7.4
20

21
22 **Fig. 14.** FTIR spectra of a) sample 1 b) sample 3 c) sample 7 d) sample 11 e) sample 14 f) sample 20
23

24 **Fig. 15.** FE-SEM Image of a) sample 1, b) sample 7, c) sample 13 and d) sample 20
25
26
27


28 **Table Captions:**
29

30
31 **Table 1.** L25 Taguchi design (4 factors each at 5 levels) (* % ratio to total PVA and GT)
32

33 **Table 2** The obtained experimental data from Taguchi method (* % ratio to total PVA and GT)
34


35 **Table 3.** Amount of R-squared (R^2) for sample 4 and 17
36

37 **Table 4.** HCQ delivery from different carriers
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



13
14
15
16
17
18
19
20
21
22
23
24
25

Fig. 1.



S

Fig. 2




Fig. 3.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 4.




Fig. 5.




Fig. 6.




Fig. 7.




Fig. 8.




Fig. 9.




Fig. 10.




Fig. 11.




Fig. 12.




Fig. 13.





Fig. 14.






Fig. 15.

Table Captions:
Table 1.

Factors	Levels				
	Level 1	Level 2	Level 3	Level 4	Level 5
PVA/GT(w/w)	1:0	0.95:0.05	0.9:0.10	0.85:0.15	0.80:0.20
%CA*wt.%	5	4	3	2	1
crosslinking time (min)	1	2	3	4	5
Fe ₃ O ₄ *wt.%	1	2	3	4	5

Table 2.

run	PVA (%w/v)	GT (%w/v)	CA*%	Crosslinking Time (min)	Fe ₃ O ₄ *%
1	2	0	5	1	1
2	2	0	4	2	2
3	2	0	3	3	3
4	2	0	2	4	4
5	2	0	1	5	5
6	1.9	0.1	5	2	3
7	1.9	0.1	4	3	4
8	1.9	0.1	3	4	5
9	1.9	0.1	2	5	1
10	1.9	0.1	1	1	2
11	1.8	0.2	5	3	5
12	1.8	0.2	4	4	1
13	1.8	0.2	3	5	2
14	1.8	0.2	2	1	3
15	1.8	0.2	1	2	4
16	1.7	0.3	5	4	2
17	1.7	0.3	4	5	3
18	1.7	0.3	3	1	4

19	1.7	0.3	2	2	5
20	1.7	0.3	1	3	1
21	1.6	0.4	5	5	4
22	1.6	0.4	4	1	5
23	1.6	0.4	3	2	1
24	1.6	0.4	2	3	2
25	1.6	0.4	1	4	3

Table 3.

run	R ² results		
	zero order	Higuchi	Hixon-Crowell
5	0.986	0.933	0.960
25	0.987	0.946	0.962

Table 4.

Carrier	T (°c)	pH	Time	%Cumulative Release	reference
pectin membranes incorporated with cellulose nanocrystals nanofibrils (CNF)	25	6.8	120 min	65%	Zambuzi et al. 2021[31]
copper and aminosilane functionalized mesoporous silica	25	7.2	120 min	58%	Olejniak et al. 2021[32]
biodegradable polymeric sodium alginate and lignosulphonic acid blends	25	7	120 min	72%	Reddy et al. 2021[33]
Fe ₃ O ₄ @SiO ₂ @GLYMO@pectin	37	7.4	120 min	42%	Sadr et al. 2020[9]
Pluronic– HCQ-MTX nanomicelles	37	7.4	5 h	80%	Magne et al. 2021[34]
calcium-alginate beads	37	8	12h	50%	Armutcu et al 2021[35]
Fe ₃ O ₄ @GT/PVA hydrogel	25	7.4	18 h	80.28 %	This study